Ironwood Pharmaceuticals is trading 5% up now at $4.25 as investors continue reacting to the August 6 earnings update and raised 2026 guidance.
- LINZESS U.S. sales guidance rose to $1.15–$1.20 billion; total revenue guidance is $460–$485 million.
- Adjusted EPS was $0.31, above consensus estimates.
- No new August 11 company press release was listed; broader indexes were nearly flat.